Search Result
Results for "
β-catenin peptide
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P1416
-
Foxy-5
Maximum Cited Publications
7 Publications Verification
|
Wnt
|
Cancer
|
|
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .
|
-
-
- HY-113283
-
|
|
Amyloid-β
Natriuretic Peptide Receptor (NPR)
α-synuclein
Transthyretin (TTR)
Claudin
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .
|
-
-
- HY-111836
-
|
|
Molecular Glues
β-catenin
|
Cancer
|
|
NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation .
|
-
-
- HY-141448
-
|
|
β-catenin
E1/E2/E3 Enzyme
|
Cancer
|
|
NRX-2663 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC50 of 22.9 μM and a Kd of 54.8 nM .
|
-
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
-
- HY-P4858
-
|
|
GSK-3
Wnt
|
Cancer
|
|
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer .
|
-
-
- HY-141450
-
|
|
β-catenin
|
Cancer
|
|
NRX-103095 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-103095 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 163 nM .
|
-
-
- HY-141449
-
|
|
Molecular Glues
β-catenin
|
Cancer
|
|
NRX-103094 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-103094 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 62 nM and a Kd of 0.6 nM .
|
-
-
- HY-P1416A
-
Foxy-5 TFA
Maximum Cited Publications
7 Publications Verification
|
Wnt
|
Cancer
|
|
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .
|
-
-
- HY-P1454
-
Fz7-21
3 Publications Verification
Ac-LPSDDLEFWCHVMY-NH2
|
Wnt
|
Cancer
|
|
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .
|
-
-
- HY-P10392B
-
|
|
β-catenin
Wnt
|
Cancer
|
|
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .
|
-
-
- HY-P1454A
-
|
Ac-LPSDDLEFWCHVMY-NH2 TFA
|
Wnt
|
Cancer
|
|
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .
|
-
-
- HY-P1589
-
|
|
β-catenin
|
Cancer
|
|
β-catenin peptide is a 8-aa peptide, and can promote thymocyte positive selection.
|
-
-
- HY-P2272
-
|
|
Wnt
β-catenin
|
Cancer
|
|
NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC50 of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h shows anti-proliferation of cancer cells .
|
-
-
- HY-P2272A
-
|
|
Wnt
β-catenin
|
Cancer
|
|
NLS-StAx-h TFA is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC50 of 1.4 μM. NLS-StAx-h TFA efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h TFA shows anti-proliferation of cancer cells .
|
-
-
- HY-P10392
-
|
|
β-catenin
Wnt
|
Cancer
|
|
aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .
|
-
-
- HY-124826
-
|
NSC 109268
|
β-catenin
|
Cancer
|
|
BC21 (NSC 109268) is a β-catenin/Tcf4 inhibitor with an IC50 of 5 μM. BC21 effectively inhibits the binding of β-catenin to Tcf4-derived peptides and suppresses β-catenin/Tcf4-driven reporter gene activity. BC21 can be utilized in cancer research .
|
-
-
- HY-P11346
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
N-Cadherin mimic peptide is a N-cadherin agonist. N-Cadherin mimic peptide promotes N-cadherin homodimerization via enhancing β-catenin signaling, inducing early chondrogenesis and cartilage matrix production in mesenchymal stem cells (MSCs). N-Cadherin mimic peptide is promising for research of MSC-based cartilage regeneration .
|
-
-
- HY-107528
-
|
|
β-catenin
GSK-3
|
Cancer
|
|
FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and β-catenin. FRATtide inhibits GSK-3 binding to Axin .
|
-
-
- HY-P11597
-
|
CY-101
|
Wnt
β-catenin
|
Cancer
|
|
Getacatetide (CY-101) is a peptide-based Wnt/β-catenin inhibitor, which can be used for the study of solid tumors .
|
-
-
- HY-P11867
-
|
|
Wnt
β-catenin
|
Others
|
|
UM206_L is a linear Wnt fragment peptide derived from conserved Wnt3a/Wnt5a sequences, inactive in soluble form but capable of activating canonical Wnt/β-catenin signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces .
|
-
-
- HY-P11867A
-
|
|
Wnt
β-catenin
|
Others
|
|
UM206_C is a circular Wnt fragment peptide derived from conserved Wnt3a/Wnt5a sequences, inactive in soluble form but capable of activating canonical Wnt/β-catenin signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1416
-
Foxy-5
Maximum Cited Publications
7 Publications Verification
|
Wnt
|
Cancer
|
|
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .
|
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
- HY-P4858
-
|
|
GSK-3
Wnt
|
Cancer
|
|
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer .
|
-
- HY-P1416A
-
Foxy-5 TFA
Maximum Cited Publications
7 Publications Verification
|
Wnt
|
Cancer
|
|
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .
|
-
- HY-P1454
-
Fz7-21
3 Publications Verification
Ac-LPSDDLEFWCHVMY-NH2
|
Wnt
|
Cancer
|
|
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .
|
-
- HY-P10392B
-
|
|
β-catenin
Wnt
|
Cancer
|
|
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .
|
-
- HY-P1454A
-
|
Ac-LPSDDLEFWCHVMY-NH2 TFA
|
Wnt
|
Cancer
|
|
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .
|
-
- HY-P1589
-
|
|
β-catenin
|
Cancer
|
|
β-catenin peptide is a 8-aa peptide, and can promote thymocyte positive selection.
|
-
- HY-P2272
-
|
|
Wnt
β-catenin
|
Cancer
|
|
NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC50 of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h shows anti-proliferation of cancer cells .
|
-
- HY-P2272A
-
|
|
Wnt
β-catenin
|
Cancer
|
|
NLS-StAx-h TFA is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC50 of 1.4 μM. NLS-StAx-h TFA efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h TFA shows anti-proliferation of cancer cells .
|
-
- HY-P10392
-
|
|
β-catenin
Wnt
|
Cancer
|
|
aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .
|
-
- HY-P11346
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
N-Cadherin mimic peptide is a N-cadherin agonist. N-Cadherin mimic peptide promotes N-cadherin homodimerization via enhancing β-catenin signaling, inducing early chondrogenesis and cartilage matrix production in mesenchymal stem cells (MSCs). N-Cadherin mimic peptide is promising for research of MSC-based cartilage regeneration .
|
-
- HY-107528
-
|
|
β-catenin
GSK-3
|
Cancer
|
|
FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and β-catenin. FRATtide inhibits GSK-3 binding to Axin .
|
-
- HY-P11597
-
|
CY-101
|
Wnt
β-catenin
|
Cancer
|
|
Getacatetide (CY-101) is a peptide-based Wnt/β-catenin inhibitor, which can be used for the study of solid tumors .
|
-
- HY-P11867
-
|
|
Wnt
β-catenin
|
Others
|
|
UM206_L is a linear Wnt fragment peptide derived from conserved Wnt3a/Wnt5a sequences, inactive in soluble form but capable of activating canonical Wnt/β-catenin signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces .
|
-
- HY-P11867A
-
|
|
Wnt
β-catenin
|
Others
|
|
UM206_C is a circular Wnt fragment peptide derived from conserved Wnt3a/Wnt5a sequences, inactive in soluble form but capable of activating canonical Wnt/β-catenin signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-113283
-
|
|
Structural Classification
Other disease
Classification of Application Fields
Ketones, Aldehydes, Acids
Disease markers
Phenols
Polyphenols
Metabolic Disease
Endogenous metabolite
Disease Research Fields
|
Amyloid-β
Natriuretic Peptide Receptor (NPR)
α-synuclein
Transthyretin (TTR)
Claudin
|
|
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
